ABUS250117C5000
- 0.15
- 0.000.00%
Arbutus Biopharma Newsroom
Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Arbutus Biopharma Analyst Ratings
Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Arbutus Biopharma's Promising Clinical Developments and Strong Financial Position Justify Buy Rating
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
Arbutus Biopharma Analyst Ratings
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Buy Rating Justified by Arbutus Biopharma's Strong Financials and Focused Clinical Strategy
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy Rating